Latest News

Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil

04 January 2021

  • - Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated
  • - The scientific approaches underlying this clinical study...

Read more

Publication of Prospectus

18 December 2020

This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase...

Read more

Notification of proposed admission to the Main Market and cancellation of trading on AIM

17 December 2020

London, New York, 17 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list...

Read more

PDMR Dealing

10 December 2020

London, New York, 10 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified...

Read more

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET

01 December 2020

NEW YORK and LONDON – 1 December 2020 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO...

Read more

PDMR Dealing

18 November 2020

London, New York, 18 November 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified...

Read more

Page 12 of 34 Previous Next